Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tg Therapeuticscmn (TGTX)

Tg Therapeuticscmn (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,404,335
  • Shares Outstanding, K 154,421
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • 60-Month Beta 2.33
  • Price/Sales 10.20
  • Price/Cash Flow 179.47
  • Price/Book 14.80
Trade TGTX with:

Options Overview Details

View History
  • Implied Volatility 75.35% ( +16.69%)
  • Historical Volatility 79.18%
  • IV Percentile 8%
  • IV Rank 16.46%
  • IV High 160.09% on 08/01/23
  • IV Low 58.65% on 03/27/24
  • Put/Call Vol Ratio 0.30
  • Today's Volume 3,274
  • Volume Avg (30-Day) 5,599
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 114,919
  • Open Int (30-Day) 116,883

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 4
  • High Estimate 0.00
  • Low Estimate -0.07
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +89.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.51 +4.82%
on 03/18/24
19.02 -20.02%
on 03/07/24
-2.42 (-13.73%)
since 02/28/24
3-Month
12.84 +18.46%
on 02/21/24
22.67 -32.91%
on 01/10/24
-2.41 (-13.68%)
since 12/28/23
52-Week
6.46 +135.45%
on 10/16/23
35.67 -57.36%
on 05/04/23
+0.56 (+3.82%)
since 03/28/23

Most Recent Stories

More News
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 15.21 (-2.31%)
Why TG Therapeutics Stock Is Crushing It Today

The biopharmaceutical company's Q3 update was music to investors' ears.

TGTX : 15.21 (-2.31%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 15.21 (-2.31%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...

TGTX : 15.21 (-2.31%)
Why TG Therapeutics Stock Is Crashing Today

The drugmaker delivered a couple of surprises in Q2.

TGTX : 15.21 (-2.31%)
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 15.21 (-2.31%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today.

APLS : 58.78 (+0.50%)
TGTX : 15.21 (-2.31%)
VKTX : 82.00 (-1.61%)
ISEE : 39.95 (+0.38%)
ALPMY : 10.7500 (-1.74%)
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TGTX : 15.21 (-2.31%)
ICUI : 107.32 (+4.31%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 15.21 (-2.31%)
3 Top Biotech Stocks Defying the Bear Market

All three companies have therapies with strong sales potential.

BIIB : 215.63 (-0.33%)
LLY : 777.96 (-0.03%)
NVS : 96.73 (+0.89%)
RHHBY : 31.9200 (+1.95%)
TGTX : 15.21 (-2.31%)
VKTX : 82.00 (-1.61%)
BGNE : 156.39 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 15.95
2nd Resistance Point 15.77
1st Resistance Point 15.49
Last Price 15.21
1st Support Level 15.04
2nd Support Level 14.86
3rd Support Level 14.58

See More

52-Week High 35.67
Fibonacci 61.8% 24.51
Fibonacci 50% 21.06
Fibonacci 38.2% 17.62
Last Price 15.21
52-Week Low 6.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar